The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Also comes with 40 trained staff and £3m of assets
Yep, another margin improving purchase with minimal dilution. This is starting to look like a well managed recovery play with limited downside risk in my view. Worth listening to Stuart
Clever strategic acquisition 👍
Interesting new acquisition - great to see the ambition for the company.
You were right to shout about it. It just keeps going.
Especially love this part of the update by Charlie about the new product opportunities exciting times ahead and paying a dividend too,
Chief executive Charlie Peppiatt said: "Positive progress has been made in the first half with increasing operational output and continued strong levels of customer engagement on new product opportunities. Full year expectations for the Group are unchanged and the outcome of our strategy review confirms a clear route to mid-teens returns in the medium term."
Peel Hunt Limited set a target price of 750 GBX for the company, which when compared to the Gooch & Housego, share price of 571 GBX at opening today (07/06/2023) indicates a potential upside of 31.5%. Trading has ranged between 388 (52 week low) and 964 (52 week high) with an average of 30,525 shares exchanging hands daily. The market capitalisation at the time of writing is £142,446,689.
H1 results did not disappoint and ghh will now go from strength to strength with the US CHIPS and Science Act now passed bringing chip manufacturing back to the western world to protect cyber security and military applications and the new push in AI making my future investment here sound. The future is so bright I gotta wear shades..
I DO NOT THINK SO - PLENTY UPSIDE LEFT OVER NEXT 6 MONTHS - STILL UNDERPRICED
Seems I called this wrong and missed the chance to top up my holding.
On the way up already
the market suggests entry levels will be lower in a couple of days.
Salary and component inflation is the problem
Absolute gift of an entry level top up time.
Gooch & Housego [LON:GHH], the specialist manufacturers of photonic components and systems, has issued a six month trading update today. Production capacity has been increased to reduce order backlogs, with revenue for the half year expected to be £71m against a comparative of £54m, with the order book now standing at £124m, broadly in line with the position from a year ago. Full year performance is expected to be in line with expectations.
Someone mopped up the sold shares this afternoon £250k bought at 460p
Half year trading update due next week probably
Being sold off before half year results..
G&H just been tipped on Vox Markets today as being in good value territory.
Just amusing myself as this is one of those rare companies that in my opinion will flourish over the forthcoming years..
Glad I sold out here it's going nowhere
Hitting ten year lows giving a great entry point for an aim company about to turn around..
GHH's defence and aerospace businesses are getting a lot of interest just now and this will only increase exponentially with western countries spending in both set to rocket due to the challenges facing world order. Meanwhile their 3rd industrial arm is getting a boost with new orders from laser engine tech in the wind turbine and carbon dioxide industrial lasers. There is also a medical diagnostic instrument order on the cards from a US based OEM customer. Back to £10 soon imho.
No surprises there. Making inroads into the inventory and production woes of last year and indication of some large deals on the horizon.
Medical Hyperspectral Imaging (MHSI) Market Booming Worldwide With Leading Key Players -Headwall Photonics, Resonon, IMEC, EVK DI Kerschhaggl, Cubert, Galileo, Specim, Gooch & Housego, Surface Optics, Norsk Elektro Optikk A/S, Wayho Technology, BaySpec
The relationship with ghh is thus
Rheinmetall Electronics UK (REUK) has awarded a £4.1M Challenger 3 contract to G&H for the supply of a custom specific variant of the Embedded Image Periscope (EIP) for integration into the Trailblazer Driver Vision System.
Another significant milestone has been achieved by the Challenger 3 Delivery Team within budget and ahead of schedule – we are moving closer to delivering one of the most capable and lethal tanks in Europe.
Challenger 3 teams from DE&S’ Land Equipment Operating Centre and the British Army, together with our industry partners Rheinmetall BAE Systems Land (RBSL) have been working to progress the CR3 programme at pace, and we can now announce that we have approved the Critical Design Review (CDR) ahead of schedule. This follows the Initial Design Review (IDR) held in March 2022 and is the culmination of an enormous amount of collaborative work. This CDR means that the design for the tanks has been agreed and that RBSL can now start building the CR3 prototypes.
The work was carried out under an £800M contract which was awarded to RBSL in 2021 to deliver 148 upgraded, fully digitalised battle tanks to the British Army. Supply-chain sub-contracts have now been awarded to UK supply chain companies, contributing to the government’s levelling up agenda. Following two key design reviews, work to modernise and expand RBSL’s production facility in Telford – which will also manufacture Boxer vehicles – is now almost complete.”
The above is a brief sumamry of what is involved in coverting tanks to ‘Challenger 3’ standard.
In a news release, they add that the fully digitalised tanks will benefit from the following:
a new 120mm smoothbore gun which uses the most advanced globally available ammunition
a new suite of sights providing tank commanders with enhanced day and night targeting abilities
a new armour solution
an active protection system
a turret that can be fitted to the tanks of allies and global partners
Significantly improved mobility through an upgraded engine and new hydrogas suspension